论文信息 - A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer - 字舞流文

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

D. Visscher | A. Chen | E. Swisher | H. Tawbi | A. Tan | V. Giranda | S. Oesterreich | S. Kaufmann | E. Chu | R. Parchment | W. Duan | H. Chew | B. Diergaarde | S. Ivy | Yiping Zhang | J. Ji | Yan Lin | B. Kiesel | J. Beumer | Leonard R. Appleman | James J. Lee | C. Belani | Tiffany A. Katz | R. Stoller | R. Morgan | Agustin A. Garcia | J. Manzo | S. Puhalla | S. Pahuja | Fei Ding | Jing Yu | A. W. Wahner Hendrickson | R. Hurley | S. Shepherd | Brian F. Kiesel